Glasgow based Biotechnology business, Fixed Phage, secures £1.5m follow-on investment to further scale development and commercialisation of bacteriophage technology in the fight against antimicrobial resistance.
The latest funding round has seen current investors, including Scottish Enterprise and London Scottish Investment Partners join a follow-on round to support the commercialisation of key programmes, which include the development and commercialisation of phage-based solutions in Animal & Veterinary health, as well as planning and development for Human health applications.
Read more HERE.
